CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
Not yet recruiting
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Phase 3
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in
adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract
obstruction
CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
Not yet recruiting
Cytokinetics
Phase 3
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in
adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract
obstruction
The Purpose of This Study is to Compare the Efficacy and Safety of Aficamten (CK-3773274) Compared With Metoprolol Succinate in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Not yet recruiting
Cytokinetics
Phase 3
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274)
compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and
left ventricular outflow tract obstruction
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Completed
Cytokinetics
Phase 1
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A
(Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT
Study) is a randomized, double-blind (with respect to aficamten and matching placebo),
positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect
of aficamten administration on QT/QTc interval.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
